IMM News: Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Pres - 4th Nov 2022, 11:00pm

annb0t

Top 20
Immutep Limited

Late-breaking abstract one of nineabstracts selected by
SITC Communications Committee to be showcased at the SITC 2022 Press Conference

Company to host Webcast on Thursday, 10th November at 5PM ET
to discuss datain Late-Breaking Oral Abstract Presentation

SYDNEY, AUSTRALIA, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for ...

>>> Read more: Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
 
Top Bottom